HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties

Through reactivating tumor-infiltrating lymphocytes, therapeutics targeting programmed cell death protein 1 (PD-1) demonstrate impressive clinical efficacy in the treatment of multiple cancers. In this report, we characterize HX008, a humanized IgG4S228P anti-PD-1 monoclonal antibody with an enginee...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jibin, Huang, Ying, Xi, Gan, Zhang, Faming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153830/
https://www.ncbi.nlm.nih.gov/pubmed/32106752
http://dx.doi.org/10.1080/19420862.2020.1724751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153830/
https://www.ncbi.nlm.nih.gov/pubmed/32106752
http://dx.doi.org/10.1080/19420862.2020.1724751

Ejemplares similares